A CITF-funded study, published by the C.D. Howe Institute, underscored that vaccine passports are aimed at protecting unvaccinated people or people who cannot be vaccinated from the risk of serious illness from COVID-19.
A study carried out by SeroTracker (a CITF-funded project), in partnership with the World Health Organization, found global SARS-CoV-2 seroprevalence (due to infection or vaccination or both) was 45.2% by end of June 2021.
In a study led by SeroTracker, CITF-funded researchers and CITF Secretariat employees, the authors present an approach to help interpret serosurvey results and distinguish between infection-acquired and vaccine-induced immunity.
Researchers at CITF-funded Serotracker present a new automated tool designed for risk of bias assessment (ROB).
Explaining the limited utility of convalescent plasma from the first phase of the COVID-19 pandemic in treating those newly infected
The continued persistence of SARS-CoV-2 infections in predominantly unvaccinated individuals has meant a continued need for therapeutics to treat those hospitalized with COVID-19.
It is increasingly clear that vaccines are among the primary solutions to the COVID-19 pandemic.
Vaccine certificates or "passports" are becoming more commonplace, with access to restaurants, event venues, and even workplaces increasingly dependent on proof of vaccination against COVID-19.
Careful vigilance of population immunity, booster vaccines, masks, and social distancing required to fend off a new COVID wave
A study out in preprint in August (and therefore not yet peer-reviewed) led by CITF Scientific Advisor Dr. Jane Heffernan and which included CITF Scientific Lead, Data Management & Analysis, Dr. David Buckeridge, modelled immunity to COVID-19 across Canada.
Cutting-edge technologies can be used to anticipate functional and clinical impact of new variants of SARS-CoV-2
In a recent review in Clinical Proteomics, Dr. Andrei Drabovich and his team from University of Alberta provide insights on the use of cutting-edge technologies to empower basic and clinical research on COVID-19.
Dr. Marc-André Langlois and his team at the University of Ottawa analyzed mutations in SARS-CoV-2 from December 2019 to December 2020, including the impact on virus biology, therapeutics and vaccine effectiveness.